Aviance Capital Partners, LLC Abb Vie Inc. Transaction History

Aviance Capital Partners, LLC

$733 Million
Q3 2024

A detailed history of Aviance Capital Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Aviance Capital Partners, LLC holds 143,096 shares of ABBV stock, worth $24.3 Million. This represents 3.86% of its overall portfolio holdings.

Number of Shares

143,096

Previous 142,647 0.31%

Holding current value

$24.3 Million

Previous $24.5 Million 15.5%

% of portfolio

3.86%

Previous 3.59%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$163.84 - $199.33 $73,564 - $89,499	449 Added 0.31%	143,096 $28.3 Million
Q2 2024 Aug 09, 2024	BUY	$154.79 - $180.76 $155,718 - $181,844	1,006 Added 0.71%	142,647 $24.5 Million
Q1 2024 Apr 17, 2024	BUY	$159.82 - $182.1 $3.04 Million - $3.46 Million	19,028 Added 15.52%	141,641 $25.8 Million
Q4 2023 Feb 06, 2024	SELL	$137.6 - $154.97 $372,070 - $419,038	-2,704 Reduced 2.16%	122,613 $19 Million
Q3 2023 Nov 06, 2023	SELL	$133.59 - $154.65 $487,069 - $563,853	-3,646 Reduced 2.83%	125,317 $18.7 Million
Q2 2023 Aug 04, 2023	SELL	$132.51 - $164.9 $4.13 Million - $5.14 Million	-31,196 Reduced 19.48%	128,963 $17.4 Million
Q1 2023 May 10, 2023	SELL	$144.61 - $166.54 $1.75 Million - $2.02 Million	-12,133 Reduced 7.04%	160,159 $25.5 Million
Q4 2022 Feb 06, 2023	SELL	$138.31 - $165.87 $174,823 - $209,659	-1,264 Reduced 0.73%	172,292 $27.9 Million
Q3 2022 Nov 09, 2022	SELL	$134.21 - $153.93 $9,126 - $10,467	-68 Reduced 0.04%	173,556 $23.3 Million
Q2 2022 Aug 08, 2022	BUY	$137.62 - $174.96 $1.95 Million - $2.48 Million	14,164 Added 8.88%	173,624 $26.6 Million
Q1 2022 May 06, 2022	BUY	$131.98 - $163.75 $255,777 - $317,347	1,938 Added 1.23%	159,460 $25.9 Million
Q4 2021 Feb 07, 2022	BUY	$107.43 - $135.93 $124,189 - $157,135	1,156 Added 0.74%	157,522 $21.3 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $470,181 - $533,726	4,419 Added 2.91%	156,366 $16.9 Million
Q2 2021 Aug 06, 2021	BUY	$105.21 - $117.21 $399,377 - $444,929	3,796 Added 2.56%	151,947 $17.1 Million
Q1 2021 Apr 29, 2021	BUY	$102.3 - $112.62 $22,710 - $25,001	222 Added 0.15%	148,151 $16 Million
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $54,652 - $73,786	679 Added 0.46%	147,929 $15.9 Million
Q3 2020 Nov 03, 2020	BUY	$85.91 - $100.83 $155,583 - $182,603	1,811 Added 1.25%	147,250 $12.9 Million
Q2 2020 Jul 24, 2020	BUY	$73.37 - $98.18 $8.98 Million - $12 Million	122,360 Added 530.18%	145,439 $14.3 Million
Q1 2020 May 05, 2020	SELL	$64.5 - $97.79 $1.46 Million - $2.22 Million	-22,703 Reduced 49.59%	23,079 $1.76 Million
Q4 2019 Feb 07, 2020	BUY	$72.13 - $90.25 $107,762 - $134,833	1,494 Added 3.37%	45,782 $4.05 Million
Q3 2019 Nov 07, 2019	BUY	$62.98 - $75.72 $616,574 - $741,298	9,790 Added 28.38%	44,288 $3.35 Million
Q2 2019 Aug 12, 2019	SELL	$65.7 - $83.98 $18,724 - $23,934	-285 Reduced 0.82%	34,498 $2.51 Million
Q1 2019 May 01, 2019	SELL	$77.14 - $90.79 $421,184 - $495,713	-5,460 Reduced 13.57%	34,783 $2.8 Million
Q4 2018 Feb 11, 2019	SELL	$77.85 - $96.01 $170,102 - $209,781	-2,185 Reduced 5.15%	40,243 $3.71 Million
Q3 2018 Nov 09, 2018	SELL	$88.91 - $98.84 $50,323 - $55,943	-566 Reduced 1.32%	42,428 $4.01 Million
Q2 2018 Aug 10, 2018	BUY	$89.78 - $106.23 $4,848 - $5,736	54 Added 0.13%	42,994 $3.98 Million
Q1 2018 May 03, 2018	BUY	$92.01 - $123.21 $204,446 - $273,772	2,222 Added 5.46%	42,940 $4.06 Million
Q4 2017 Feb 13, 2018	BUY	$89.56 - $98.21 $12,986 - $14,240	145 Added 0.36%	40,718 $3.94 Million
Q3 2017 Nov 09, 2017	BUY	$69.85 - $89.22 $2.83 Million - $3.62 Million	40,573	40,573 $3.61 Million

Others Institutions Holding ABBV

# of Institutions

3,817

Shares Held

1.25B

Call Options Held

13M

Put Options Held

10M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $300B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviance Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviance Capital Partners, LLC with notifications on news.

Account

Aviance Capital Partners, LLC Abb Vie Inc. Transaction History